Dr. Kevin Anthony Codorniz, MD

Dr. Codorniz practices at Loma Linda University Medical Cente - Center for Restorative Neurology - HOPD in Loma Linda, California.

Dr. Codorniz's NPI, 1871702316, was assigned on May 22, 2007. Dr. Codorniz graduated from Loma Linda University School Of Medicine in 2005. Dr. Codorniz holds California license A99953.

Dr. Codorniz's primary practice is Loma Linda University Medical Cente - Center for Restorative Neurology - HOPD, at 11370 Anderson St, Loma Linda, CA 92354.

Dr. Codorniz's primary practice is Loma Linda University Medical Cente - Center for Restorative Neurology - HOPD in Loma Linda, California. Dr. Codorniz is also affiliated with Loma Linda University Medical Center. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Codorniz to 1 more hospital outpatient department and 1 medical group, each named with a free account. Dr. Codorniz's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Codorniz practices, 3 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Codorniz's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Codorniz is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dr. Codorniz is licensed in California.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, high cholesterol, osteoporosis, overactive thyroid, testicular dysfunction and underactive thyroid among the conditions Dr. Codorniz treats.

CMS data shows 379 Medicare services from Dr. Codorniz across 5 procedure codes in 2024, for 133 Medicare patients. Medicare paid $20,985 for them.

CMS counts 133 Medicare patients who saw Dr. Codorniz in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 44% are also on Medicaid. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Codorniz's median patient age at 66, with 66% women.

In 2024, Dr. Codorniz wrote 1,335 Medicare Part D claims for 149 patients. 42% of them were for generic drugs. CMS names the drug for 1,080 of them, across 28 drugs with 11 or more claims each, at $434,302 in total drug cost. In 2023, CMS named 1,233 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Codorniz for performance year 2024, reported as part of a group. Dr. Codorniz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Codorniz as offering telehealth.

Dmand AI links 3 papers to Dr. Codorniz in 2025. The most frequent topics are Administration, Inhalation, Blood Glucose and Diabetes Mellitus, Type 1. Dr. Codorniz has published most often in Diabetes Care. Dr. Codorniz's most frequent co-authors are Halis Kaan Akturk, MD, Grazia M. Aleppo, MD and Anuj Bhargava, MD.

Dmand AI links Dr. Codorniz to 1 clinical trial. Conditions studied include Diabetes Mellitus, Type 1 and Autoimmune Diseases.

CMS Open Payments shows 63 general payments to Dr. Codorniz from 8 drug and device companies from 2016 to 2024. Travel and lodging make up the largest share, 50% of the total. Medtronic MiniMed, Inc. paid the most, $2,511.

Dmand AI lists 1 award for Dr. Codorniz, most recently CMS Stage 1 EHR in 2013.

Dr. Codorniz graduated from Loma Linda University School Of Medicine in 2005.

Dr. Codorniz is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.